Issues related to FDA drug approval processes, including consistent application of regulatory flexibility for rare disease therapies such as BCMA-targeted CAR-T therapy for AL amyloidosis.
2026 · 3rd Quarter (July 1 - Sep 30)
IMMIX BIOPHARMA INC.
Filed by AXADVOCACY GOVERNMENT RELATIONS.
Open official filingSource-reported fields
Filing overview
- Type
- 3rd Quarter - Report
- Posted
- Oct 19, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- AXADVOCACY GOVERNMENT RELATIONS
- Client
- IMMIX BIOPHARMA INC.
- Filing UUID
- 27a5d77b-9e97-4be1-81bb-914b08ba2073
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.